Feedback PLC Trading Update & Director Appointment (4500N)
01 Junho 2022 - 3:00AM
UK Regulatory
TIDMFDBK
RNS Number : 4500N
Feedback PLC
01 June 2022
Feedback plc
Trading Update and Director Appointment
-- Trading for the financial year ended 31 May 2022 materially ahead of market expectations
-- Annemijn Eschauzier joins the Board adding strong healthcare
and digital skill sets, as Tim Irish steps down
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
specialist clinical communication company, is pleased to announce
that it has continued its strong momentum into the second half of
2022 and now expects to report revenue for the financial year ended
31 May 2022 materially ahead of market expectations. This follows
the previously announced progress with the Company's flagship
product Bleepa (R) and additional technology license fees arising
from the Company's partnership with Imaging Engineering LLC
(partnership as announced 13 January 2020) booked at the year-end.
The Board expects to provide a full 2022 year-end operational and
trading update in mid-June 2022.
Appointment of Annemijn Eschauzier to the Board
Annemijn Eschauzier has been appointed to the Board of directors
as a Non-Executive Director with immediate effect.
Annemijn brings significant global leadership experience with a
career spanning well over 25 years in the Healthcare sector. She
started her career at GlaxoSmithKline before moving to GE
Healthcare, where she held a variety of leadership positions for
over 15 years becoming Chief Marketing Officer Women's Health in
September 2017. Since leaving GE Healthcare in March 2021, Annemijn
has joined Hardian Health, a company which provides strategic
services to navigate the digital health sector. In addition,
Annemijn. holds other non-statutory Board member roles and has a
bachelor's degree in Dutch Law and Business Administration.
Annemijn will be joining the Board as Tim Irish steps down as
NED with immediate effect, after five years with the Company. Tim
leaves to pursue new opportunities in the medical sector.
Rory Shaw, Chairman of Feedback, commented: "We are delighted to
report that revenue is expected to be materially ahead of
expectations. Importantly, we are developing relationships with
existing and new partners and believe that we are at an inflection
point for growth as we continue to see the benefits of investing
the funds raised last year.
"We are delighted to welcome Annemijn to the Board and believe
that she will bring a wealth of experience as we steer the Company
ever faster towards the commercial growth of our technologies. The
Board and I would like to sincerely thank Tim Irish for his
fantastic service to the Company over the course of his five years
as a NED, we wish him well in all his future endeavours and are
delighted that he remains such a strong advocate for the company
and our technologies as he goes forward in his new roles"
Anna Marina ("Annemijn") Eschauzier (aged 64) does not currently
hold any directorships and has no previous directorships (within 5
years). Annemijn Eschauzier has confirmed that there is no further
information to be disclosed pursuant to paragraph (g) of Schedule 2
of the AIM Rules.
Further information on Feedback and its products can be found on
the Company's website:
https://fbkmed.com/feedback-plc/reports-and-presentations/
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited
(NOMAD and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome 07980 541 893 or 07748 325 236
About Feedback
Feedback plc is a specialist clinical communications business,
with a mission to improve the efficiency and quality of
communications for frontline clinicians and hospitals with a key
focus on building solutions that enhance access to high quality
patient data.
Feedback has developed a toolkit of clinical communications
apps. Its core, regulatory approved product is Bleepa, a
revolutionary medical imaging app enabling remote and secure
communications between frontline clinicians and teams. CareLocker
is an evolutionary GDPR compliant patient-centric cloud
architecture - its proprietary technology enables an easy route to
creation and mobilisation of individual healthcare records. Bleepa
Box is a specialist tool to enable image transfer from remote
settings to the Bleepa platform over mobile networks.
The Company has a number of growth opportunities domestically
and internationally across a range of markets including the NHS,
the veterinary market and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based revenue model
is expected to provide increasing levels of visibility as the
Company grows its customer base.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTEALSFDSNAEFA
(END) Dow Jones Newswires
June 01, 2022 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Feedback (LSE:FDBK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
